论文部分内容阅读
目的观察FOLFIRINOX方案一线治疗晚期胰腺癌的临床疗效及毒副反应。方法2011年11月至2015年1月,对江苏省肿瘤医院收治的转移性胰腺癌患者12例给予FOLFIRINOX方案一线治疗,2个周期化疗后影像学及实验室检查评价疗效,并观察毒副反应。结果 12例患者中8例PR,4例SD,无PD。疾病控制率100%。达到临床受益反应标准的共8例(67%)。6例患者CA199下降大于30%。12例患者均未出现致死性毒副反应。结论 FOLFIRINOX方案一线治疗晚期胰腺癌的临床疗效好,毒副反应可耐受,改良的FOLFIRINOX方案结合外科手术可能成为今后胰腺癌治疗的新方向。
Objective To observe the clinical efficacy and toxicity of first-line FOLFIRINOX regimen in the treatment of advanced pancreatic cancer. Methods From November 2011 to January 2015, 12 patients with metastatic pancreatic cancer admitted to Cancer Hospital of Jiangsu Province were given first-line treatment with FOLFIRINOX regimen. Imaging and laboratory tests were performed after 2 cycles of chemotherapy to evaluate the efficacy and toxicity of side effects . Results Of the 12 patients, 8 were PR and 4 were SD without PD. Disease control rate of 100%. A total of 8 patients (67%) met the clinical benefit response criteria. 6 patients CA199 decreased more than 30%. None of the 12 patients experienced lethal toxicity. Conclusion FOLFIRINOX first-line treatment of advanced pancreatic cancer has good clinical efficacy and tolerability. The improved FOLFIRINOX regimen combined with surgery may become a new direction for the treatment of pancreatic cancer in the future.